Search Results

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell therapy company, the latter of which will inherit the Galapagos name.

Galapagos NV and Blood Centers of America announced that they have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s network in the U.S.

Five years ago, Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at the original signing.

Galapagos NV announced its first quarter 2024 financial results and provided a business update and outlook for the remainder of 2024.

Galapagos NV announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings held on 30 April 2024 were approved.

Galapagos NV announced the successful completion of the transaction to transfer its Jyseleca® business to Alfasigma S.p.A.

Galapagos NV announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

Galapagos NV and Alfasigma S.p.A. announced that they have signed an agreement to transfer Galapagos’ Jyseleca® business to Alfasigma, marking a significant milestone in Galapagos’ transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology.